Halozyme Therapeutics stockHALO
Halozyme Therapeutics trades at $122.96, 8.2% below its 52-week high (Oct 30, 2026). The price is above its 50- and 200-day averages, i.e. in an uptrend. +82.7% year to date, +80.0% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Nov 5, 2026.
- Market pulseHalozyme Therapeutics Inc is scheduled to announce earnings today after market close
- Market pulseHalozyme Therapeutics posts Q3 2026 revenue $493M (+39% YoY), non-GAAP EPS $2.39, beating estimates and raising 2026 revenue and earnings guidance
- PR NewswireHALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Ratings, candles, signals and the screener for HALO — after you log in
Open the terminalFrequently asked questions about Halozyme Therapeutics
What is the Halozyme Therapeutics stock price?
At the close on Nov 5, 2026: $122.96 (−5.66% on the day). 52-week high: $134.00 on Oct 30, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Halozyme Therapeutics report earnings?
The next quarterly report is on Nov 5, 2026. Last quarter, earnings per share changed +48% year over year, revenue +48%.
Does Halozyme Therapeutics pay dividends?
No, Halozyme Therapeutics does not pay dividends.
Where does Halozyme Therapeutics trade and how to buy it?
Ticker HALO, exchange Nasdaq. You can buy it through a broker with access to US exchanges.
Should I buy Halozyme Therapeutics now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for HALO are in the terminal after you log in.